Tuberc Respir Dis.  2005 Jul;59(1):77-85.

Clinical Course of Probable Idiopathic Pulmonary Fibrosis

Affiliations
  • 1Division of Pulmonology, Department of Internal Medicine, Gachon Medical School, Gil Medical Center, Incheon, Korea. jsw@ghil.com
  • 2Division of Pulmonary and Critical Care Medicine, Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea.

Abstract

BACKGROUND: According to the 2002 consensus report of the American Thoracic Society/European Respiratory Society (ATS/ERS), idiopathic pulmonary fibrosis (IPF) was classified as biopsy proven or probable IPF. Probable IPF is defined as those with distinctive features that allow for a confident diagnosis of IPF/usual interstitial pneumonia (UIP) within an appropriate clinical setting. The determination of the clinical course of probable IPF, as diagnosed by the ATS/ERS criteria, was studied.
METHODS
Between March 1995 and August 2002, 36 patients with probable IPF, from two tertiary referral hospitals, were enrolled in this study. The clinical characteristics, prognostic factors and treatment efficacy of these patients were retrospectively evaluated.
RESULTS
The mean age of the subjects was 65 +/- 6 years. The one and 3 year survival rates were 82.4 and 50.3%, respectively, and a median survival period of 42.0 months. The total cell count of bronchoalveolar lavage was higher in the death than the survival group (p<0.05). No survival benefits were found in the cytoxan and steroid treatment groups compared with other treatment groups.
CONCLUSION
These results suggest that the clinical course of probable IPF may be similar to that of biopsy-proven UIP. However, atypical patients must undergo an open lung biopsy for confirmation of the diagnosis.

Keyword

Idiopathic pulmonary fibrosis; Probable IPF

MeSH Terms

Biopsy
Bronchoalveolar Lavage
Cell Count
Consensus
Cyclophosphamide
Diagnosis
Humans
Idiopathic Pulmonary Fibrosis*
Lung
Lung Diseases, Interstitial
Retrospective Studies
Survival Rate
Tertiary Care Centers
Treatment Outcome
Cyclophosphamide
Full Text Links
  • TRD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr